Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Value of Fibroscan® in Assessing the Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B and Monitoring Changes by Antiviral Therapy: Faraday Study

NCT06573190 is registered in ClinicalTrials.gov with Yaşar Bayındır, MD as lead sponsor.

NCT NCT06573190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06573190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Value of Fibroscan® in Assessing the Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B and Monitoring Changes by Antiviral Therapy: Faraday Study
Lead sponsor
Yaşar Bayındır, MD
Phase
Observational
Overall status
Completed
Start date
January 2, 2023
Completion date
May 15, 2024
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b, hepatic steatosis